Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00150982 | Alefacept Mechanism of Action in Psoriasis | PHASE2 | COMPLETED | 9 | — | — | Sep 1, 2003 | Feb 1, 2005 | Aug 7, 2008 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Mechanism of action of alefacept | DRUG | - |
Inclusion Criteria * Alefacept is indicated for the treatment of adult patients (18 years or older) with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. Patients must have at least one plaque of least 2.5 cm in diameter (for biopsies). Exclusion...